Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)

@inproceedings{Ou2016FactorsAW,
  title={Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)},
  author={Shuqi Ou and Yiyun Tang and Andrew D. Polli and Keith David Wilner and Patrick T. Schnell},
  booktitle={Cancer medicine},
  year={2016}
}
Decreases in heart rate (HR) have been described in patients receiving crizotinib. We performed a large retrospective analysis of HR changes during crizotinib therapy. HRs from vital-sign data for patients with anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer enrolled in PROFILE 1005 and the crizotinib arm of PROFILE 1007 were analyzed. Sinus bradycardia (SB) was defined as HR <60 beats per minute (bpm). Magnitude and timing of HR changes were assessed. Potential risk factors… CONTINUE READING
BETA

Similar Papers

Loading similar papers…